Technology Acquisitions and License Agreements (Details Textual) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2010	Nov. 30, 2014	Sep. 30, 2014	May 09, 2014	Sep. 30, 2013	Dec. 31, 2005
Xenogenics Corporation [Member] | Foreclosure Sale Agreement [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payments For Purchase Of Assets	$ 400,000
Total Milestones Payments Due		4,300,000
Xenogenics Corporation [Member] | Rutgers License Agreement [Member]
Technology Acquisitions And License Agreements [Line Items]
License Fee Paid	50,000
License Maintenance Fee Payable			50,000	25,000	25,000
Unpaid Patent Costs	136,000			75,665
Liabilities Subject to Compromise, Debt and Accrued Interest				8,375
Xenogenics Corporation [Member] | Milestone One [Member] | Foreclosure Sale Agreement [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones	300,000
Future Royalties Milestone Payments Description	(i) initiation of pivotal Generation 2 stent human clinical trials, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $3,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments), and (iii) a change of control of Xenogenics
Xenogenics Corporation [Member] | Milestone Two [Member] | Foreclosure Sale Agreement [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones	1,000,000
Future Royalties Milestone Payments Description	(i) regulatory approval by any regulatory authority in a European Union member country, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $5,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments); and (iii) a change of control of Xenogenics
Xenogenics Corporation [Member] | Milestone Three [Member] | Foreclosure Sale Agreement [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones	3,000,000
Future Royalties Milestone Payments Description	(i) regulatory approval by the U.S. Food and Drug Administration, (ii) execution of an agreement in which Xenogenics grants a third party rights to develop or exploit the purchased assets, valued at no less than $5,000,000 (including all up-front payments and the net present value of any future royalty/milestone payments); and (iii) a change of control of Xenogenics.
Amarin Neuroscience Limited [Member] | Milestone One [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones						500,000
Amarin Neuroscience Limited [Member] | Milestone Two [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones						1,000,000
Amarin Neuroscience Limited [Member] | Milestone Three [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones						1,500,000
Amarin Neuroscience Limited [Member] | Milestone Four [Member]
Technology Acquisitions And License Agreements [Line Items]
Cash Payable Upon Milestones						1,000,000
Rhode Island Hospital [Member] | Scenario, Forecast [Member]
Technology Acquisitions And License Agreements [Line Items]
Percentage Royalty Payable		5.00%
Maximum Payable For Royalties		$ 550,000
Percentage Of Royalty Payable, After Payment Of Total Royalties		2.00%